Signalling pathways that mediate skeletal muscle hypertrophy and atrophy
David J. Glass
David Glass is in Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown NY, 10591-6707, USA
david.glass@regeneron.com
Atrophy of skeletal muscle is a serious consequence of numerous diseases, including cancer and AIDS. Successful treatments for skeletal muscle atrophy could either block protein degradation pathways activated during atrophy or stimulate protein synthesis pathways induced during skeletal muscle hypertrophy. This perspective will focus on the signalling pathways that control skeletal muscle atrophy and hypertrophy, including the recently identified ubiquitin ligases muscle RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx), as a basis to develop targets for pharmacologic intervention in muscle disease.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
